Geron shares have fallen nearly 20 percent year-to-date. The biotech company has recently announced plans to discontinue its discovery research and companion diagnostics program and cut its workforce from 64 to 44 positions.
Going forward ... (see research report)
Copyright ® 2016. The Bedford Report. All Rights Reserved.